Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.

Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026: Geneva, Switzerland Saturday, April 25, 2026, 14:00 Hrs [IST] Addex ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators for the treatment of autoimmune disease, today ...

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 ...

AI images and video may be impressive, but they’re not ‘professional’-standard – an issue that a new research project seeks ...

Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...

Researchers reported favorable safety and tolerability for CS1 after 12 months of treatment in patients with pulmonary arterial hypertension.

While the primary motor endpoint showed modest improvement, more notable effects were observed in non-motor domains.

ULIXACALTAMIDE maintained response in essential tremor in a Phase III randomized withdrawal study at AAN 2026. The topline ...